REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 1,477,339 shares changed hands during trading, an increase of 143% from the previous session's volume of 608,766 shares.The stock last traded at $10.47 and had previously closed at $9.63.
Wall Street Analysts Forecast Growth
RGNX has been the subject of a number of research analyst reports. Raymond James reissued an "outperform" rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright upped their price target on REGENXBIO from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Chardan Capital restated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a report on Tuesday, October 22nd. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Finally, Barclays decreased their price target on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.64.
Check Out Our Latest Analysis on REGENXBIO
REGENXBIO Stock Up 5.4 %
The company has a 50 day moving average of $10.47 and a 200-day moving average of $12.21. The stock has a market capitalization of $502.88 million, a P/E ratio of -2.02 and a beta of 1.23.
Insider Buying and Selling
In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now directly owns 11,286 shares of the company's stock, valued at $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 13.13% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Redmile Group LLC boosted its stake in REGENXBIO by 21.0% during the first quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company's stock valued at $95,901,000 after buying an additional 790,866 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in REGENXBIO by 258.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company's stock worth $9,552,000 after acquiring an additional 588,773 shares during the period. Vanguard Group Inc. lifted its holdings in shares of REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company's stock valued at $102,756,000 after buying an additional 436,043 shares during the last quarter. Artal Group S.A. acquired a new stake in shares of REGENXBIO during the 1st quarter valued at about $5,268,000. Finally, Integral Health Asset Management LLC lifted its holdings in shares of REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after buying an additional 190,000 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
